heart failure News
-
Volunteer for Committee and Leadership Positions for the 2023-2025 Term
The Heart Failure Society of America is your association and we would love for you to get involved. Volunteering for committee and leadership positions at HFSA helps you develop professionally, facilitates networking with other heart failure leaders, and will positively impact the heart failure field. Plus, it’s fun and rewarding! This year's volunteering application period will be open ...
-
Heart Failure Awareness 365: Nutrition/Diet/Exercise
March 2023's Heart Failure Awareness 365 campaign is focusing on: Nutrition/Diet/Exercise. While these three things are important for any individual's everyday health, they can have an even bigger impact if you're living with heart failure. Not only can properly managing these parts of your health alleviate heart failure symptoms, but they can also slow the disease's progression. ...
-
Economic Considerations in the Management of Heart Failure Explored on New Episode of the Heart Failure Beat Podcast
Tune into this episode of HF Beat to hear our co-hosts interview Paul Heidenreich, MD, FHFSA, a co-author of the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure about economic considerations in the management of HF. On "From Failure to Function", Priya dives into the late breaking trials from ACC.23 and Michael reviews three papers on HFpEF on HF Rounds. ...
-
Genomic Advances in Heart Failure
Heart failure is a significant global health issue. More than half of the people who develop heart failure die within 5 years. Current treatments do not help the largest group of these patients – those with heart failure with preserved ejection fraction (HFpEF) – and have limited effectiveness for those with reduced injection fraction (HFrEF). HFpEF has been called the greatest unmet ...
-
Groundbreaking Use of Radar-Equipped Vests in a Hospital Promises to Improve the Care of Heart Failure Patients
Dr. Dan Bensimhon tends to see things differently. At a conference, the director of the Cone Health Advanced Heart Failure Clinic noticed a small vest that uses military technology to measure fluid in the lungs of patients. The company saw the vest as a way for people with heart failure to catch fluid buildup at home before it became a problem. Bensimhon saw the vest as an opportunity to ...
-
High-tech vest may help heart failure patients avoid hospital stays
When people with congestive heart failure feel short of breath and fatigued, it means their lungs are slowly filling with fluid. But by the time they feel those symptoms, they may need hospitalization to correct the ...
-
Hi-tech vest may help keep heart failure patients out of hospital
Doctors at The Ohio State University Richard M. Ross Heart Hospital are testing a high-tech vest which measures fluid inside the lungs from outside a person's clothing. It could be a new way to prevent repeated trips to the hospital for the nearly six million Americans living with heart ...
-
Ohio State Studies If High-tech Vest Can Help Manage Heart Failure at Home
Doctors at The Ohio State University Richard M. Ross Heart Hospital are testing a high-tech vest which measures fluid inside the lungs from outside a person’s clothing. It could be a new way to prevent repeated trips to the hospital for the nearly six million Americans living with heart ...
-
Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company’s BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing ...
-
Cone Health using radar technology to better treat heart failure
Congestive heart failure is one of the most common reasons elderly people end up in the hospital. When this happens fluid builds up in the lungs and patients have trouble breathing. Cone Health is the first in the country to use a new technology to measure the amount of fluid in the lungs in the inpatient hospital setting. “Now we have a device that lets us know in 90 seconds whether there ...
-
Radar Vest Could Help Patients With Congestive Heart Failure Reduce Hospital Visits
There might be some good news for the nearly six million Americans with congestive heart failure. Those patients are often in and out of hospitals because their lungs fill with fluid. But as CBS2’s Dr. Max Gomez reports, a new device – a “radar vest” – could prevent those hospital ...
-
IFEMA MADRID will held Heart Failure Congress in 2022
This announcement comes a few months after the ESC selected the Institution as host venue for its global congress for 2025, confirming the attractiveness of IFEMA MADRID and Madrid as a host city for large high-level medical congresses. The HFA comprises more than 10,000 members, and past Heart Failure congresses have hosted 5,500 to 6,000 delegates at their in-person editions. The ...
-
New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Oak Ridge, TN – March 23, 2023 — Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and ...
-
CARMAT anticipates implants of its Aeson artificial heart to resume in October 2022
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical needby providing a therapeuticalternative to people suffering from end-stage biventricular heart failure,issues an update on its activities and ...
By Carmat
-
Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for th e Treatment of Chronic Heart Failure
Hanover, Germany, December 11, 2018 - Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School ...
-
CVRx Launches a new Barostim Programmer
MINNEAPOLIS, July 12, 2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim Programmer, which was approved by the U.S. Food and Drug Administration (FDA) earlier this year. The second-generation programmer has a modernized design, operates on an upgraded cellular network ...
By CVRx
-
Presenting Monogenic Heart Failure Disease Modeling in Kyoto
https://www.termis.org/wc2018/ On September 7th, CSO speaks about monogenic disease modeling using NuHeart™ technology during TERM for heart, blood vessel & lung session. 99-O-5: Personalized micro-3D human heart tissues for orphan drug development Tetsuro Wakatsuki,Neil Daily,Pinar Kemanli, Michael Greenberg,Jennifer Strande InvivoSciences, Inc. Madison Wisconsin, USA, ...
-
Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier society focused on improving Heart Failure outcomes, a condition that more than 6 million Americans ...
-
CVRx Launches new Barostlm NE02 Implantable Pulse Generator
The new Borostim NE02 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians MINNEAPOLIS, Nov. 3, 2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has launched its new Barostim NE02™ IPG. ...
By CVRx
-
Ancora Heart Announces Expansion of U.S. Early Feasibility Study
Santa Clara, Calif.– February 3, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of enrollment in its CorCinch HFrEF Early Feasibility Study (EFS), which is evaluating the AccuCinch® Ventricular Repair System in patients with reduced ejection ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you